Very Late Onset Neuromyelitis Optica Spectrum Disorders
Overview
Affiliations
Background And Purpose: Neuromyelitis optica spectrum disorder (NMOSD) often presents in the elderly with an insidious onset of symptoms and aggressive progression. There have been anecdotal cases of very late onset (VLO)-NMOSD, but case series reports are rare. The aim of this retrospective study was to clarify the clinical features of VLO-NMOSD.
Methods: According to the age at onset, we classified patients with NMOSD into three subgroups: ≤49 years, early onset NMOSD (EO-NMOSD); 50-69 years, late onset NMOSD (LO-NMOSD); and ≥70 years, VLO-NMOSD. We evaluated the clinical characteristics, magnetic resonance imaging (MRI) findings, laboratory data, and immunotherapies of the groups.
Results: Overall, 12 men and 64 women with a median (interquartile range) age at onset and duration of disease of 42.0 (29.0-55.8) years and 70.0 (16.3-143.0) months, respectively, were included. Eight (11%) patients had VLO-NMOSD, 22 (29%) had LO-NMOSD, and 46 (61%) had EO-NMOSD. Patients with EO-NMOSD had a significantly longer interval between episodes as well as time between the first symptom and diagnosis of NMOSD than did those with VLO-NMOSD and LO-NMOSD (p = 0.046). Optic neuritis and nerve lesions on MRI were significantly less frequent in patients with VLO-NMOSD than in those with LO-NMOSD and EO-NMOSD (p = 0.002 and p = 0.028, respectively). In contrast, patients with VLO-NMOSD had higher nadir Expanded Disability Status Scale and Nurick scale scores and a significantly longer spinal lesion length than did those with LO-NMOSD and EO-NMOSD (p = 0.029, p = 0.049, and p = 0.032, respectively).
Conclusions: Patients with VLO-NMOSD tend to develop severe myelitis with long cord lesions but not optic neuritis.
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
Arnett S, Chew S, Leitner U, Hor J, Paul F, Yeaman M J Neurol. 2024; 271(8):4794-4812.
PMID: 38958756 PMC: 11319503. DOI: 10.1007/s00415-024-12452-8.
Luo W, Shi Z, Kong L, Wang X, Zhou H Eur J Neurol. 2023; 31(3):e16178.
PMID: 38117536 PMC: 11235930. DOI: 10.1111/ene.16178.
Yang Q, Lai C, Meng C, Chang Q, Wei N, Wang J Neurol Sci. 2023; 45(5):2191-2197.
PMID: 37982973 DOI: 10.1007/s10072-023-07187-9.
Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.
Demuth S, Collongues N, Audoin B, Ayrignac X, Bourre B, Ciron J Neurology. 2023; 101(4):e438-e450.
PMID: 37290967 PMC: 10435052. DOI: 10.1212/WNL.0000000000207443.
Zhang W, Jiao Y, Cui L, Zhang Y, Jiao J, Jin M Ther Adv Neurol Disord. 2023; 16:17562864231162420.
PMID: 36993936 PMC: 10041617. DOI: 10.1177/17562864231162420.